Fact-checked by Grok 2 weeks ago

8-Hydroxyquinoline

8-Hydroxyquinoline, also known as oxine or quinolin-8-ol, is a bicyclic heterocyclic with the molecular formula C₉H₇NO and a molecular weight of 145.16 g/mol. It exists as a white to off-white crystalline powder with a , a of 73–75 °C, and a of approximately 267 °C, and it is sparingly soluble in water but soluble in organic solvents like and . The compound features a quinoline ring system with a hydroxyl group attached at the 8-position, enabling it to function as a monoprotic bidentate chelating agent that coordinates with metal ions such as Fe²⁺, Cu²⁺, and Zn²⁺ via its nitrogen atom and deprotonated oxygen. This chelation property is central to its diverse applications, including stabilization of hydrogen peroxide, extraction of metals in analytical chemistry, and production of dyes. In medicinal contexts, 8-hydroxyquinoline and its derivatives, such as and PBT2, exhibit promising pharmacological potential due to their ability to modulate metal , with applications in treating neurodegenerative disorders like by targeting amyloid-beta aggregates and in anticancer therapies through induction of via metal-dependent pathways. Additionally, it serves as an and agent, effective against pathogens including Mycobacterium tuberculosis and Staphylococcus aureus, and finds industrial use as a in and materials like and timber.

Structure and Properties

Molecular Structure

8-Hydroxyquinoline is a bicyclic featuring a fused benzene ring and a ring, with a hydroxyl group attached at the 8-position, directly adjacent to the nitrogen atom in the ring. Its molecular formula is C₉H₇NO, and the molecular weight is 145.16 g/. The compound exhibits keto-enol tautomerism, interconverting between the enol form (8-hydroxyquinoline, with the hydroxyl group) and the form (8-quinolinone, featuring a and hydrogen on ). The enol form predominates due to its greater stability, as determined by calculations at the B3LYP/6-311G** level, which show the OH tautomer as the most stable configuration for 8-hydroxyquinoline. In the enol form, the structure maintains across both rings, with the hydroxyl group participating in an intramolecular to the (O-H⋯N). The form, while less prevalent, influences certain reactivity patterns by allowing alternative bonding sites. X-ray crystallography of 8-hydroxyquinoline confirms the planarity of the molecule, with the fused ring system lying in a single plane to maximize π-conjugation and the intramolecular . Selected bond lengths include C8-O1 at 1.357(2) Å, indicative of a C-O in the form, and N1-C2 at 1.321(3) Å, reflecting partial double-bond character in the ring. Bond angles, such as C2-N1-C8A at 117.24(18)°, support the aromatic .

Physical Properties

8-Hydroxyquinoline appears as a white to off-white or faintly yellow crystalline powder with a odor. It has a of 73–76 °C and a of 267 °C at 760 mmHg. The is 1.034 g/cm³ at 20 °C. Regarding , it is slightly soluble in water at 0.055 g/100 mL (20 °C) but highly soluble in organic solvents such as , acetone, and . The compound is stable under normal conditions but darkens upon exposure to light.

Chemical Properties

8-Hydroxyquinoline exhibits weak acidity due to its hydroxyl group, with a of approximately 9.8, similar to that of typical ( ~10) owing to the adjacent nitrogen facilitating and stabilization of the resulting oxinate anion through and hydrogen bonding. This acidity enables the formation of salts in basic media, enhancing its solubility in aqueous environments. The compound also displays basic character from the nitrogen, with the of its conjugate around 5.0, indicating moderate basicity comparable to itself. This in acidic conditions increases in mineral acids, as the charged interacts more favorably with . 8-Hydroxyquinoline is susceptible to oxidation by strong oxidizing agents, potentially leading to reactive intermediates or decomposition products. It shows sensitivity to light, darkening or discoloring upon exposure, which necessitates storage in amber containers or under inert atmospheres to maintain purity. In terms of general reactivity, 8-hydroxyquinoline undergoes preferentially on the electron-rich ring, while the ring is less reactive due to its electron-deficient nature.

Synthesis and Production

Laboratory Synthesis

One common laboratory method for synthesizing 8-hydroxyquinoline is the Skraup-Doebner-von Miller reaction, which involves the acid-catalyzed cyclization of o-aminophenol with . In this procedure, o-aminophenol is mixed with concentrated (95-100%), and is added gradually while maintaining the temperature at 70-80°C initially, followed by heating to 135-140°C for 4-5 hours under . The reaction proceeds via dehydration of to form an acrolein-like intermediate, which condenses with the aromatic amine and ortho-hydroxy group of o-aminophenol, leading to ring closure and aromatization to yield 8-hydroxyquinoline. To enhance the yield, o-nitrophenol is often included as an oxidant, along with ferrous sulfate, preventing side reactions from incomplete oxidation. The simplified reaction scheme is as follows: \ce{C6H4(NH2)(OH) + C3H8O3 ->[H2SO4][135-140^\circ C] C9H7NO + H2O + byproducts} Alternative laboratory routes include the diazotization of 8-aminoquinoline, followed by of the resulting diazonium . This method is particularly useful when starting from precursors. Another approach begins with the reduction of 8-nitroquinoline to 8-aminoquinoline, followed by the diazotization- sequence. Following synthesis, the crude 8-hydroxyquinoline is typically purified by to remove impurities, or by as a . Recrystallization from is also commonly employed. Laboratory-scale reactions generally afford 50-70% overall yields based on o-aminophenol, depending on the oxidant and temperature control. Safety precautions are essential due to the corrosive nature of concentrated and the risk of exothermic reactions at elevated temperatures (135-140°C); reactions should be conducted in a with appropriate protective equipment, and temperature monitoring is critical to prevent or explosions from overheating.

Commercial Production

The primary industrial method for producing 8-hydroxyquinoline is a modified Skraup synthesis, involving the reaction of o-aminophenol with , which generates , in acidic media, typically , to form the quinoline ring. Variants use directly. This process has been optimized for large-scale operations, achieving yields exceeding 80%. can serve as an acrolein precursor in variants of this method, generated under acidic conditions, making it cost-effective for bulk production. An alternative route involves the sulfonation of at the 8-position to yield quinoline-8-sulfonic acid, followed by caustic fusion with at elevated temperatures to replace the group with a hydroxyl group. This method is employed in some facilities where is readily available as a starting material. As of , the worldwide annual production of quinoline derivatives exceeds 2,000 tons, with 8-hydroxyquinoline comprising a major portion. Major manufacturing hubs are in and , which account for a significant portion of global supply and exports to regions including and . Cost factors include raw material sourcing, such as o-aminophenol derived from reduction, and energy inputs for high-temperature reactions, influencing overall in these regions. Environmental considerations in production focus on managing acidic byproducts from sulfuric acid use, with wastewater treatment often involving neutralization and adsorption processes to remove residual organics like unreacted o-aminophenol. Efforts toward greener production include exploring catalytic alternatives to harsh acids and microwave-assisted variants of the Skraup reaction to reduce energy consumption and waste generation.

Applications

Analytical Chemistry

8-Hydroxyquinoline, also known as oxine, is widely employed as a gravimetric in qualitative and of metals due to its ability to form sparingly soluble chelate complexes with various metal ions. In gravimetric methods, it precipitates metals such as , magnesium, and as insoluble oxinates, enabling their isolation and quantification by weighing the dried precipitate. For , the procedure involves buffering an acetic acid of the sample with , adjusting the to approximately 6.8 with using bromcresol as an indicator, and adding a hot ethanolic of 8-hydroxyquinoline to form the yellow Al(oxine)3 precipitate, which is then filtered, washed, dried at 140°C, and weighed. This method accurately determines up to 50 mg of , with potential interferences from other metals mitigated by prior separations like for or selective for magnesium. Similar gravimetric approaches apply to magnesium, forming Mg(oxine)2·2H2O, and as Zn(oxine)2, often in ammoniacal solutions for optimal . In spectrophotometric applications, 8-hydroxyquinoline forms colored complexes with metals like iron(III) and , allowing quantification via UV-Vis . The iron(III)-oxine complex exhibits maximum absorbance at 359 nm in , following Beer's law over 1–14 µg/mL, while the complex is measured similarly after into solvents. These methods enable simultaneous determination of multiple metals using chemometric techniques, with detection limits reaching trace levels suitable for environmental and pharmaceutical samples. Extraction chromatography leverages the of metal-8-hydroxyquinoline complexes for separation from aqueous matrices by partitioning into organic phases or onto immobilized supports. For instance, silica-immobilized 8-hydroxyquinoline facilitates chelation chromatography, selectively retaining and eluting metals like and from complex samples, while solvent extraction with or other organics isolates traces of prior to . These techniques achieve separations at ppm levels, enhancing sensitivity for detection in water and biological fluids.

Medicinal Uses

8-Hydroxyquinoline derivatives, particularly iodoquinol (diiodohydroxyquinoline), have been employed as amebicides and antidiarrheal agents for treating intestinal amebiasis caused by Entamoeba histolytica. These compounds act primarily within the intestinal lumen, where they exhibit amebicidal activity against both trophozoite and encysted forms of the parasite by chelating essential metal ions, such as ferrous iron, which disrupts protozoal metabolism. However, as of December 2024, the FDA considers oral iodoquinol an unapproved new drug and has initiated actions to remove it from the market in the US. Historically, clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) served a similar role as an oral intestinal amebicide, introduced in 1934 for managing amebic dysentery and related diarrheal conditions through comparable metal chelation mechanisms; oral use was discontinued in many countries following reports of severe neurotoxicity (subacute myelo-optic neuropathy, SMON) in the 1970s and 1980s. In dermatological applications, 8-hydroxyquinoline derivatives like are utilized topically as agents for treating infections, including those caused by dermatophytes and yeasts. Formulations such as 3% creams or ointments are applied to affected areas 2 to 4 times daily, with treatment durations typically limited to 2–4 weeks for conditions like or to minimize risks of irritation or sensitization. These concentrations (around 3–5%) provide effective local action while limiting systemic exposure, and recent studies have confirmed their utility in restoring in inflammatory lesions. Investigational efforts have explored 8-hydroxyquinoline derivatives, including clioquinol and PBT2 (a second-generation analog), for Alzheimer's disease therapy due to their ability to chelate excess zinc and copper ions associated with amyloid-beta plaques. A small 2003 pilot study of clioquinol suggested slowed disease progression. Early phase IIa trials of PBT2 (250 mg daily for 12 weeks) demonstrated dose-dependent reductions in cerebrospinal fluid amyloid-beta levels and modest cognitive improvements in mild-to-moderate Alzheimer's patients. However, subsequent clinical trials, such as the 2014 phase 2 IMAGINE trial, have yielded inconclusive results, with no clear evidence of sustained efficacy or disease modification, leading to ongoing challenges in advancing these compounds to approval. Dosage and administration vary by derivative and indication: historically, iodoquinol was given orally at 650 mg three times daily (up to 2 g/day) for 20 days in adults for amebiasis, while is applied topically as a 3% 2–4 times daily. Pharmacokinetically, iodoquinol exhibits poor and erratic gastrointestinal , confining its action to the intestinal , followed by hepatic metabolism and fecal excretion; topical shows minimal , supporting its safety for dermatological use.

Industrial and Other Uses

8-Hydroxyquinoline and its derivatives serve as effective fungicides in , inhibiting the of phytopathogenic fungi such as those affecting seeds and other crops through and mechanisms. In applications, it is authorized for use until 2032 under specific regulatory conditions to control fungal pathogens. For , copper-8-quinolinolate formulations are widely applied to protect freshly cut lumber and timber from sapstain, mold, and discoloration-causing fungi like Pullularia pullulans. In the dyes and pigments industry, 8-hydroxyquinoline acts as a key intermediate for synthesizing azo dyes, which exhibit strong affinity for fabrics and provide vibrant coloration with good fastness properties. Derivatives such as 5-chloro-8-hydroxyquinoline are utilized as fluorescent whitening agents to enhance brightness and in textiles and paper. As a , 8-hydroxyquinoline protects metals including , , and aluminum in aqueous environments by forming adherent chelate films on surfaces, reducing degradation rates in settings like pipelines and equipment. This application extends to cooling systems, where it mitigates in metal components exposed to corrosive fluids. Emerging industrial uses include its role as a in organic light-emitting diodes (OLEDs), where metal complexes like tris(8-hydroxyquinoline)aluminum (Alq₃) enable efficient and have been foundational since the for technologies. The global OLED materials market, incorporating such 8-hydroxyquinoline-based compounds, is projected to expand from $1.68 billion in 2025 to $4.53 billion by 2032, driven by demand in and lighting.

Coordination Chemistry

Chelating Properties

8-Hydroxyquinoline acts as a bidentate in metal , coordinating through the oxygen atom of the deprotonated hydroxyl group and the atom of the ring. This arrangement forms a stable five-membered chelate ring with the metal ion, enhancing the thermodynamic stability of the complex due to the . The of the hydroxyl group (pKa ≈ 9.9) is essential for the formation of the most stable anionic chelate, while the has a conjugate acid pKa ≈ 5.1, affecting at lower pH. The process is pH-dependent, with optimal conditions often in the range of 4–6, where the is predominantly in its neutral form (protonated hydroxyl, unprotonated ), minimizing competition from protons on the while allowing coordination; the proximity of donor atoms facilitates intramolecular upon . The stability of these complexes is quantified by formation constants, with representative values illustrating the ligand's affinity for different metals; for instance, the 1:1 complex with Al³⁺ has log K = 14.9, while for Cu²⁺ it is log K = 12.4, reflecting stronger binding to trivalent ions. These constants vary with and solvent but indicate high stability for transition and post-transition metals. The complexation is exothermic (ΔH < 0), primarily driven by enthalpic contributions from coordinate bond formation, while the favorable entropy (ΔS > 0) arises from the release of solvated molecules from the metal and ligand upon binding. Selectivity for trivalent metals over divalent ones stems from the higher charge density of ions like Al³⁺ and Fe³⁺, which allows for stronger electrostatic interactions within the chelate ring compared to lower-charged divalent ions such as Cu²⁺ or Zn²⁺. This preference is evident in the order of stability constants, where trivalent complexes often exhibit log K values exceeding those of divalent counterparts by several units under comparable conditions. Factors like ligand basicity and steric accessibility further modulate selectivity, but the inherent geometry of the bidentate site favors compact, high-charge-density metals.

Metal Complexes

8-Hydroxyquinoline (8-HQ) forms stable coordination complexes with various metal ions due to its bidentate chelating ability through the nitrogen of the quinoline ring and the oxygen of the phenolic group, resulting in neutral or charged species depending on the metal and stoichiometry. These complexes often exhibit octahedral or square planar geometries and are characterized by vibrant colors and enhanced solubility in organic solvents compared to the free ligand. Key examples include tris(8-hydroxyquinolinato)aluminum(III), copper(II) bis(8-hydroxyquinolinato), and iron(III) tris(8-hydroxyquinolinato), each with distinct structural features and applications in materials science and analytical techniques. Tris(8-hydroxyquinolinato)aluminum(III), commonly denoted as Alq₃, is a octahedral where the aluminum(III) is coordinated to three deprotonated 8-HQ ligands via N,O-bidentate , forming a mer-isomer in the solid state with approximate C₃ symmetry. It is synthesized by refluxing 8-HQ with an aluminum salt, such as aluminum isopropoxide, in or isopropanol under basic conditions ( ≈ 10) at around 50–80°C, followed by and recrystallization. Alq₃ is a benchmark material in organic light-emitting diodes (OLEDs), emitting green at approximately 525 nm with high (up to 15–20% in devices) and thermal stability up to 400°C, enabling its use as an electron-transport and emissive layer in displays. Its reveals a three-dimensional stabilized by intermolecular bonds and π–π interactions between quinoline rings. The copper(II) bis(8-hydroxyquinolinato) complex, [Cu(C₉H₆NO)₂], adopts a square planar geometry with the Cu(II) ion equatorially bound to two 8-HQ ligands, exhibiting a characteristic green color due to d–d transitions in the visible region. Synthesis involves reacting 8-HQ with a copper(II) salt, such as copper acetate, in ethanol or aqueous media at room temperature, yielding the neutral complex with high purity after filtration and drying. This complex demonstrates antifungal activity against various fungi, attributed to its ability to disrupt microbial membranes, and its crystal structure shows a planar core with short Cu–O and Cu–N bonds (≈1.9 Å) and intermolecular Cu···O interactions forming dimers. It is sparingly soluble in water but highly soluble in chloroform and acetone, enhancing its utility in solution-based applications. The iron(III) tris(8-hydroxyquinolinato) complex, [Fe(C₉H₆NO)₃], is a red-colored neutral species with an octahedral coordination sphere, where the high-spin Fe(III) ion is chelated by three 8-HQ ligands, showing magnetic susceptibility consistent with five unpaired electrons. It is prepared by mixing ferric chloride with 8-HQ in a buffered aqueous-ethanol solution (pH 5–7) and extracting the complex into chloroform, where it exhibits maximum absorbance at 575 nm. This complex is notably stable in acidic media (pH > 3) and organic solvents like chloroform, with solubility exceeding 10 mg/mL, but it hydrolyzes in strongly basic conditions. It has been employed in histochemical staining for detecting iron deposits in tissues, forming insoluble colored precipitates that provide high-contrast visualization under microscopy, as detailed in early methods for pathological analysis. Zinc(II) bis(8-hydroxyquinolinato), Znq₂, and magnesium(II) bis(8-hydroxyquinolinato), Mgq₂, are tetrahedral or distorted octahedral complexes used as fluorescent probes due to their strong emission in the green-yellow region (500–550 nm) upon UV excitation. These are synthesized by reacting 8-HQ with zinc or magnesium salts in alcoholic solvents under mild heating, yielding volatile, sublimable solids. Crystal structures of Znq₂ reveal a monomeric tetrahedral arrangement with Zn–O and Zn–N bond lengths of ≈1.95 Å, while Mgq₂ shows similar coordination but with enhanced rigidity due to the smaller ionic radius. Their photoluminescence quantum yields reach 40–60% in thin films, making them suitable for sensing applications and OLED alternatives to Alq₃.

Biological Activity

Antimicrobial Activity

8-Hydroxyquinoline (8-HQ) demonstrates antimicrobial activity through its ability to chelate essential divalent metal ions, such as iron (Fe²⁺) and (Zn²⁺), which are vital for the function of microbial enzymes involved in and . By binding these metals, 8-HQ disrupts metal in and fungi, impairing enzymatic activities required for energy production and synthesis, ultimately leading to microbial . This multi-target mechanism contributes to its broad efficacy against various pathogens, as the chelation affects multiple essential processes simultaneously. Representative minimum inhibitory concentrations (MICs) for 8-HQ range from 16–32 μM against Staphylococcus aureus, including methicillin-resistant strains (MRSA), and approximately 28 μM against Candida albicans, highlighting its potency at low concentrations comparable to standard antibiotics like ampicillin. The antimicrobial spectrum encompasses Gram-positive bacteria such as S. aureus and Enterococcus faecalis, and yeasts including C. albicans. Certain metal complexes of 8-HQ exhibit synergistic effects with antibiotics, such as and imipenem, enhancing their efficacy against resistant strains through fractional inhibitory concentration indices below 0.5. As of 2023, 8-HQ derivatives have shown broad susceptibility against emerging fungal pathogens like .

Other Pharmacological Effects

8-Hydroxyquinoline and its derivatives exhibit neuroprotective potential primarily through their ability to chelate metal ions such as and , which are implicated in the aggregation of β-amyloid peptides in models. studies have demonstrated that these compounds inhibit metal-induced Aβ1-42 aggregation, with one derivative showing an of 5.64 μM for self-induced aggregation and effectively reducing plaque formation by modulating amyloid-bound metals. This disrupts the catalytic activity of metals that promote and protein misfolding, offering a mechanistic basis for in cellular models like PC12 cells exposed to . Derivatives of 8-hydroxyquinoline have shown anticancer activity in various cancer lines. In models, conjugates incorporating 8-hydroxyquinoline moieties exhibit potent antiproliferative effects with values around 7.7 μM, highlighting their potential as targeted therapies through metal chelation-induced . The profile of 8-hydroxyquinoline indicates moderate acute oral , with an LD50 of 1200 mg/kg in rats, suggesting relative at low doses but caution with higher exposures. Historically, the derivative , used at high doses (300 mg/day to 3.5 g/day), was associated with subacute myelo- (SMON), a neurodegenerative involving , peripheral nerve demyelination, and visual disturbances, leading to its withdrawal as an oral agent in the 1970s. Anti-inflammatory effects of 8-hydroxyquinoline are mediated through , which modulates inflammatory pathways such as signaling and production in activated macrophages. In lipopolysaccharide-induced inflammation models, 8-hydroxyquinoline inhibits inducible expression, reducing pro-inflammatory release. This metal-dependent mechanism has shown promise in preclinical models by alleviating joint inflammation through restoration of metal homeostasis and suppression of .

History

Discovery

8-Hydroxyquinoline was first synthesized in 1880 by the Austrian chemist Hugo Weidel and his student Albert Cobenzl while working at the First Chemical Institute of the University of Vienna. Their work represented an early milestone in the chemistry of quinoline derivatives, building on Weidel's prior research into cinchona alkaloids. The synthesis involved the decarboxylation of oxycinchoninic acid, a compound obtained by oxidizing cinchoninic acid derived from cinchonine. Weidel and Cobenzl achieved this by heating the acid with lime, which removed the carboxyl group and yielded the desired product as a base that could be isolated and purified. Initial characterization confirmed the compound as a hydroxy-substituted through , which aligned with the empirical formula , and a reported of 75 °C. These properties distinguished it from related quinolines and supported its identification as 8-hydroxyquinoline, later verified through further studies. Weidel detailed the reaction and findings in a in Monatshefte für Chemie, marking the compound's formal to the .

Developments and Controversies

Following its in 1880, 8-hydroxyquinoline (8-HQ) saw early developments in the early as an and agent, with derivatives like introduced in the 1930s for treating amoebic dysentery, fungal infections, and traveler's diarrhea. By the 1940s, its strong chelating properties were recognized, leading to applications in for detecting trace metals such as iron, , and . In the , research expanded its potential, including studies on its activity against and , which spurred the development of halogenated derivatives for broader clinical use. The 1970s marked a pivotal shift with renewed focus on metal for therapeutic purposes, particularly in neurodegenerative diseases; by the 1980s, investigations into antimalarial effects highlighted its interference with parasite metal . The late 1990s and 2000s brought significant advancements in , with 8-HQ like entering Phase II trials for due to their ability to chelate excess metals and inhibit amyloid-beta aggregation. A second-generation analog, PBT2, improved blood-brain barrier penetration and underwent Phase IIa trials by , demonstrating cognitive benefits in early studies, though development faced setbacks from impurities. Recent developments since the emphasize anticancer and antiviral applications, with metal-chelating complexes showing promise in inducing via redistribution and inhibiting . As of 2025, ongoing research continues to explore 8-HQ for anticancer, , and neurodegenerative treatments, with new syntheses and reviews highlighting their pharmacological potential. A major controversy arose in the 1960s–1970s when , a key 8-HQ derivative, was linked to an outbreak of subacute myelo-optic neuropathy (SMON) in , affecting over 10,000 individuals with symptoms including vision loss, neuropathy, and a 5% fatality rate, prompting its global withdrawal from oral use by 1970. The causality debate persists, as SMON cases were rare outside , potentially due to genetic factors like high-prevalence single nucleotide polymorphisms in ABCC4 and genes that increase sensitivity to the drug's neurotoxic effects, such as depletion and axonal degeneration. Further complicating matters, manufacturing issues introduced carcinogenic contaminants like 5,7-diiodo-8-hydroxyquinoline, exacerbating toxicity concerns and leading to regulatory bans in multiple countries. Toxicity studies have revealed 8-HQ's potential for liver and damage at high doses, as well as diabetogenic effects through zinc-dependent disruption of pancreatic β-cells, though these risks are dose-dependent and mitigated in controlled chelate forms. Despite these issues, ongoing balances 8-HQ's therapeutic potential against its historical toxicities, with calls for genetic screening to enable safer repurposing in metal-imbalance disorders.